More changes are afoot at Takeda Pharmaceutical, which has been revamping in light of the patent loss of its central drug, diabetes treatment Actos, FierceBiotech reports. CEO Deborah Dunsire is retiring from Millennium, the unit Takeda bought about 5 years ago, as Millennium's oncology R&D is rolled up into the parent company's global research organization. Dunsire's CEO position was eliminated in that move. Her responsibilities will be assumed by her business development chief, Anna Protopapas. The Japanese drugmaker revealed the management shakeup in a terse announcement today about the unit, developer of the cancer treatment Velcade. Story | More